A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Clinical trial NCT07376629 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07376629
- Sponsor
- Huabo Biopharm Co., Ltd.
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-14
- Primary completion
- 2027-01-15
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.